Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection

Vita, Serena; Zuccalà, Paola; Savinelli, Stefano; Mascia, Claudia; Rossi, Roberto; Schiavone, Francesco; Marocco, Raffaella; Tieghi, Tiziana; Iannetta, Marco; Nijhawan, Parni; Zingaropoli, Maria Antonella; D’Ettore, Gabriella; Vullo, Vincenzo; Mastroianni, Claudio Maria; Lichtner, Miriam

doi:10.1155/2020/2781350

Cited by 3 publications

(2 citation statements)

References 39 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on the effects of HCV used fresh or cryopreserved peripheral blood mononuclear cells (PBMCs) or monocyte-derived DCs (moDCs) and a limited number of phenotypic markers [17][18][19][20][21][22][23][24][25]. Isolation, cryopreservation and differentiation alter the phenotype and function of PBMCs and moDCs.…”

Section: Discussionmentioning

confidence: 99%

High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

Herderscheê¹,

Heinonen²,

Fenwick³

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

Herderscheê¹,

Heinonen²,

Fenwick³

et al. 2022

Clinical Microbiology and Infection

View full text Add to dashboard Cite

“…The immunological response after eradication of HCV using IFN-free DAA therapies is not well defined. Several studies suggest a partial immunological recovery after treatment [ 42 , 43 , 44 ]. In our study, we found a different immune profile in the two populations in the monocyte and lymphocyte compartments as well as in levels of soluble markers after DAA treatment.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects

Zuccalà

Latronico

Marocco

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

In the direct-acting antiviral (DAA) era, it is important to understand the immunological changes after HCV eradication in HCV monoinfected (mHCV) and in HIV/HCV coinfected (HIV/HCV) patients. In this study, we analyzed sub-populations of monocytes, dendritic cells (DCs), T-lymphocytes and inflammatory biomarkers following initiation of DAA in 15 mHCV and 16 HIV/HCV patients on effective antiretroviral therapy at baseline and after sustained virological response at 12 weeks (SVR12). Fifteen age- and sex-matched healthy donors (HD) were enrolled as a control group. Activated CD4+ and CD8+ T-lymphocytes, mDCs, pDCs, MDC8 and classical, non-classical and intermediate monocytes were detected using flow cytometry. IP-10, sCD163 and .sCD14 were assessed by ELISA while matrix metalloproteinase-2 (MMP-2) was measured by zymography. At baseline, increased levels of IP-10, sCD163 and MMP-2 were found in both HIV/HCV and mHCV patients compared to HD, whereas sCD14 increased only in HIV/HCV patients. After therapy, IP-10, sCD163 and sCD14 decreased, whereas MMP-2 persistently elevated. At baseline, activated CD8+ T-cells were high in HIV/HCV and mHCV patients compared to HD, with a decrease at SVR12 only in HIV/HCV patients. Activated CD4+ T-cells were higher in HIV/HCV patients without modification after DAAs therapy. These results suggest complex interactions between both viruses and the immune system, which are only partially reversed by DAA treatment.

show abstract

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C

Novikova,

Kokorev,

Konstantinov

et al. 2023

jour

View full text Add to dashboard Cite

Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.Materials and methods. 112 patients with HCV (n=112) were examined, in whom the risk of developing the metabolic syndrome was determined using a specially developed method. In 58 patients, a high risk of developing metabolic syndrome was identified. This cohort of patients was divided into two groups: group 1 (n=26) who took sofosbuvir and velpatasvir and group 2 (n=32) who did not take AVT. Patients were periodically examined and observed for 2 years. At the final stage of observation, a comparative analysis of laboratory and instrumental data was carried out in patients in two comparison groups.Results. At the start of AVT, HCV patients with a high risk of developing metabolic syndrome were found to be over-weight, moderately pronounced stage of liver fibrosis (F2 according to METAVIR), high viral load, increased transaminases, total low-density lipoprotein cholesterol, atherogenic coefficient, insulin, glucose. Two years after the etiotropic therapy in HCV patients with a high risk of developing the metabolic syndrome, normalization of blood lipid metabolism, glucose, insulin levels and a decrease in the concentration of total thyroxine were registered.Conclusion. Etiotropic therapy with direct antiviral drugs in patients with chronic hepatitis C reduces the relative risk of developing the metabolic syndrome by 6,3 times.

show abstract

Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection

Cited by 3 publications

References 39 publications

High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects

Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C

Contact Info

Product

Resources

About